Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 4Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Herpes Simplex 1Glioblastoma 1Fatigue Syndrome, Chronic 1Fatigue 1Castleman Disease 1

Interventions

Valganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Immune Reconstitution Inflammatory Syndrome × Valganciclovir × Clear all
NCT03296553 2022-01-27

Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.

National Institute of Cancerología

Phase 2 Completed
40 enrolled 6 charts
Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi, Immune Reconstitution Inflammatory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡